| 产品描述: | TNO155 是一种 protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2 /src homology region 2 domain phosphatase /PTPN11) 的抑制剂,对应的IC50值为0.011 μM。TNO155具有潜在的抗肿瘤活性。 |
| 靶点: |
SHP-2 (Cell-free assay):0.011 μM;Phosphatase |
| 体内研究: |
TNO155 is a potent and selective first-in-class inhibitor of wild-type SHP2, with high oral bioavailability and BCS class I properties. The oral bioavailability of TNO155 in mouse, rat and money are 78%, 86%, and 60%, respectively. |
| 细胞实验: |
Cell lines: PC-14 cells Concentrations: 3 μM Incubation Time: 24 h Method: PC-14 cells were treated with nazartinib (0.1 or 0.3 µM), 3 µM TNO155, or the combination of nazartinib and TNO155 for 4 hours or 24 hours. |
| 参考文献: |
1. I. Braña, C. Serrano. GIST DISEMINADO: NUEVOS ENS 2. Liu C, et al. Clin Cancer Res. 2021 Jan 1;27(1):342-354. |
| 溶解性: |
Soluble in DMSO、Ethanol |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.37 ml |
11.85 ml |
23.699 ml |
| 5 mM |
0.474 ml |
2.37 ml |
4.74 ml |
| 10 mM |
0.237 ml |
1.185 ml |
2.37 ml |
| 50 mM |
0.047 ml |
0.237 ml |
0.474 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |